Objectives: We describe failure rates of 198 patients with bone and joint infection (BJI), including prosthetic joint infection and diabetic foot osteomyelitis, managed through the Glasgow centre for outpatient parenteral antibiotic therapy (OPAT) over a period of 4 years. Outcomes following initial intravenous antimicrobial therapy and a median follow-up time of 60 weeks are described.
Introduction
Over the last 30 years, outpatient parenteral antibiotic therapy (OPAT) has come into mainstream clinical care in the USA and is increasingly used in Europe. 1 -3 Reduction in the risk of healthcare-associated infection, quicker return to work or education for the patient, improvement in quality of life for those requiring long-term antimicrobial therapy and reduction in healthcare costs 4, 5 are all important patient and health system benefits.
Numerically, skin and soft tissue infections are the most common infections treated (usually with short-term therapy), whilst bone and joint infections (BJIs), including prosthetic joint infection, 6 are the second most common treatment group. Such infections, although heterogeneous, often require lengthy courses of intravenous (iv) antibiotics in otherwise healthy patients and, therefore, are well suited to management via OPAT. Despite this, there is a paucity of published data specifically reporting outcomes of patients treated in this setting. 5,7 -10 We report the outcome of 198 patients with BJI, including prosthetic joint infection and diabetic foot osteomyelitis, managed through the Glasgow OPAT centre over a period of 4 years. Among this heterogeneous group of conditions, we show that OPAT can be used to deliver treatment with high success rates for some conditions and, amongst those who do less well, we identify factors that may contribute to their poor outcome.
Patients and methods
This was a retrospective series of all cases of BJI managed at the Glasgow OPAT centre (based at The Brownlee Unit, Gartnavel General Hospital, Glasgow nurses, with support from a clinical pharmacist, an infectious diseases physician and junior medical staff based at the infectious diseases unit. Ambulant patients with a variety of BJIs who require iv antibiotic therapy are referred to OPAT by orthopaedic, diabetic and other medical specialties based throughout NHS Greater Glasgow and Clyde (population 1.25 million). In each case, the choice and duration of antimicrobial therapy was determined by the infectious diseases physician (R. A. S.). Venous access and patient education regarding the care of central venous catheters was provided by the specialist OPAT nurses. Patients were either taught to self-administer antibiotics at home or had treatment administered by the nursing staff. In the latter cases, patients either attended the OPAT nurse-led treatment centre or were visited at home. Decisions regarding these administration techniques were made by the nurses, based on issues such as co-morbid medical or surgical conditions, social situation and acceptability of selfadministration. Patients were reviewed regularly in the OPAT outpatient clinic by either a consultant or a registrar in infectious diseases during their course of therapy.
A prospectively maintained registry of all patients attending OPAT was examined for cases of BJI, using the definitions outlined below. Once identified, patient case records were reviewed, and data extracted and entered into a Microsoft w Excel database. Only the first episode of OPATtreated BJI was included for each patient.
Case definition
Patients were classified into seven groups according to the site of infection. All patients with diabetic foot or stump infections were classified as a single group (DFI). Patients with infected knee and hip replacements were classified separately (PK and PH, respectively). The metalwork group included infections of other surgical hardware, such as shoulder replacements, metal pins or plates (MWI). Vertebral osteomyelitis or discitis were co-classified (VOM), with native joint septic arthritis (SA) and osteomyelitis affecting other bones (OM) forming additional groups.
Data collection
Data were collected from patient case records on patient demographics and diagnosis, microbiology, source of culture (wound swab, surgical isolate or blood culture), antibiotic choice, duration and side effects, and outcome.
The data was anonymized and there was no direct research-related contact with patients. Informed consent was, thus, not required. All activity was conducted in accordance with Declaration of Helsinki national and institutional standards.
Definition of treatment failure
Therapeutic outcome at the end of iv therapy was determined by the infectious diseases physician in conjunction with the referring specialist and a conservative definition was used, encompassing both clinical failure and failure of the OPAT process.
Success
Success was defined as completion of the initial prescribed therapy with signs of clinical and/or radiological improvement, a reduction in inflammatory markers, and no further iv therapy prescribed thereafter, without any unplanned readmission or serious adverse event within 4 weeks of completion of iv therapy. Although some patients continued oral antibiotic therapy beyond the end of iv therapy, monitoring of this was not included in the study.
Early failure
Early failure was recorded where the prescribed course of OPAT was not successful in eliciting either a cure or major improvement, as defined by one or more of the following criteria: (i) there was a need to continue iv therapy beyond the original prescribed course; (ii) there was a need for unanticipated surgery to control the infection (e.g. surgical debridement, amputation) within 4 weeks of completion of the initial prescribed iv therapy; (iii) the OPAT course was interrupted for any other reason (e.g. admission to hospital for a related or unrelated reason); and (iv) any evidence of relapse or recurrence of infection within 4 weeks of completion of the initial prescribed iv antimicrobial therapy.
Late failure
Late failure was defined as any evidence of recurrence of infection, relapse or reinfection ≥4 weeks after completing the initial prescribed iv therapy or if the patient died for any reason.
In 97 of those cases for whom no up-to-date follow-up information was available from the OPAT registry or from the medical notes, letters were sent to the patient's primary care physician and the referring consultant, requesting additional information.
Antibiotic management
The choice and duration of antibiotic therapy was decided by the infectious diseases consultant, and was guided by positive microbiology where available. In general, teicoplanin was used for the treatment of Gram-positive infections when methicillin-resistant infection was suspected or proven, or in the presence of b-lactam allergy or when patients were unable to self-administer iv antibiotics. Otherwise, once daily ceftriaxone was used for susceptible and/or mixed organism infections. Either meropenem or piperacillin/tazobactam was used for other resistant Gram-negative infections. Patients receiving thrice weekly iv teicoplanin had weekly trough levels performed at 72 h post-dose, as previously described. 11 In staphylococcal infections, a second oral agent to which the organism was susceptible was routinely used (usually sodium fusidate or rifampicin) in conjunction with the iv agent. Overall, 175/198 (88.4%) of patients received oral antibiotics, either in conjunction with or for a period of time following iv therapy.
Analysis
Analysis was done using STATA version 10 (Stata Corp., College Station, TX, USA). Logistic regression analysis was performed, examining risks for initial treatment failure using factors relevant to the initial presentation. Firstly, univariate analysis was done and, subsequently, multivariate analysis was conducted on factors that were significant or of borderline significance (P, 0.1).
Cox regression analysis was then performed on data censored from follow-up for recurrence of infection, death from any cause and when lost to follow-up. The follow-up period was 24 months, maximum. Initially, univariate hazard ratios were obtained and, subsequently, multivariate analysis was conducted on factors that were significant or of borderline significance (P,0.1). Kaplan-Meier plots were produced using STATA.
Results

Characteristics of the cohort
One hundred and ninety-eight cases of BJI treated through OPAT were identified from the OPAT registry: 39 diabetic foot/stump osteomyelitis (DFI); 40 prosthetic knee infections (PK); 25 prosthetic hip infections (PH); 23 other metalwork-associated infections Management of bone and joint infections through OPAT 409 JAC (MWI), including 1 ankle replacement and 4 shoulder replacements; 20 native joint septic arthritis (SA); 30 non-joint osteomyelitis (OM); and 21 vertebral osteomyelitis (VOM) ( Table 1) .
Over half of the patients were male (63.6%) and almost half were aged .60 years (48.9%) ( Table 1) . Positive microbiology was present in 84.3% of cases. A small number of patients had no positive microbiology pertaining to their current infection, but had previously had methicillin-resistant Staphylococcus aureus (MRSA) isolated from other anatomical sites (5 patients, 2.53% of the cohort); these were analysed within the MRSA group, as this result dictated their treatment. For those patients with no positive microbiology, although the possibility that the presentation was not due to infection exists, the clinical suspicion of underlying infection was high enough to warrant referral Mackintosh et al.
for iv antibiotics by the referring team and high enough to warrant treatment after review by the responsible infectious diseases specialist. As such, these patients were included in the study. Overall, the most commonly isolated organism was S. aureus and, of these, 60.2% were MRSA. Among those with DFI, S. aureus infection accounted for 41% of positive cultures, with 76.5% of these being MRSA. Sixteen percent of positive cultures were polymicrobial and, of these, the largest percentage was in those with diabetic-related infections (29.7%).
The most frequently used iv antibiotics were teicoplanin and ceftriaxone, with 96.5% of individuals in this cohort receiving initial treatment with one of these agents. For those receiving iv teicoplanin, individual median 72 h trough teicoplanin levels were calculated. Five patients did not have levels taken. The overall median of the individual median levels was 26.2 mg/L (range 6.2 -46.9 mg/L). Overall, 20 individuals (10.1%) suffered an adverse reaction to their initial prescribed iv therapy. Of these, 16 had an adverse reaction to teicoplanin, 2 to ceftriaxone, 1 to meropenem and 1 to piperacillin/tazobactam. The most common adverse reaction was rash, occurring in 9/20 patients, followed by leucopenia or thrombocytopenia, occurring in 4/20 patients. Other reactions included vomiting (3/20), fever (2/10), tinnitus (1/20) and acute kidney injury (1/20).
Risk factors for early failure
Univariate analysis was used to select factors for a multivariate model examining the risk of failing the initial prescribed OPAT therapy, as per the definitions described in the text. The oldest group of patients (aged .80 years) had an increased risk of failing in univariate analysis [odds ratio 7.81 (95% confidence interval 1.26-48.4); P ¼ 0.027)], although no information was available regarding co-morbidities. This risk remained significant in the multivariate analysis ( Table 2 ). Those presenting with DFI also had an excess risk of failing compared with other BJIs (Table 2) .
Despite the median age of those in whom MRSA was isolated being greater than of those with no MRSA isolated (64 versus 56 years; P¼ 0.0008, Wilcoxon rank sum), MRSA infection, both where isolated alone and in cases in which it was isolated along with another organism, was associated with an increased risk of immediate failure, both in univariate and multivariate analyses where age was included as a variable (Table 2 ). This does not appear to be related to the length of the initial iv therapy, with 86.7% of those with MRSA infection receiving .28 days of iv therapy and 85.8% of those without MRSA receiving .28 days iv therapy, and was independent of antibiotic choice.
Isolation of coagulase-negative staphylococci was associated with a significant increase in the likelihood of initial failure in the multivariate model (Table 2 ). In contrast, isolation of methicillinsusceptible S. aureus (MSSA) was not associated with any increase in the risk of early failure. This probably explains the lack of any association with early failure of S. aureus infection as a whole (data not shown). 
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Longitudinal follow-up
The median duration of follow-up was 60 weeks (range 6 -104 weeks). Figure 1 shows a Kaplan -Meier plot of time to treatment failure for all patients, showing all follow-up data available. A total of 59 patients (29.8%) either failed their initial treatment by the definitions outlined, re-presented with a recurrence or relapse of their infection, or died during the follow-up period.
Of those who failed, 55 (93.2%) did so within the first 12 months following OPAT treatment.
In univariate Cox regression analysis, as with early failure, presenting with a DFI was strongly associated with clinical failure, compared with any other presenting diagnosis (Table 3 and Figure 2 ). Isolation of MRSA was associated with poor outcome over the follow-up period in the univariate and multivariate analyses, compared with those with no organism isolated (Tables 3 and 4) .
In the multivariate Cox regression analysis, DFI remained positively associated with long-term failure, compared with other presenting diagnoses, as did being in the oldest age group and having MRSA ( Table 4) .
Discussion
We report 198 cases of BJI managed through OPAT and followed for up to 24 months. The overall success rate following initial iv therapy was 86.4%, although this differed according to diagnosis, ranging from 71.8% success rate for diabetic osteomyelitis to 100% for metalwork-related infection (including 1 infected ankle replacement and 4 infected shoulder replacements). Over the period of follow-up, 73.2% of patients remained infection free.
Data from France in 2001 examined 30 cases of BJI treated through OPAT and found 93% cured at 24 months. 5 Notably, in this study, the mean age was 44 years and there was no mention of diabetes as a co-morbidity in any of the cases. In a study from the USA in 2003, 30.6% of individuals overall had a recurrence and, of these, 95% occurred in the first 12 months of follow-up, 12 similar figures to those presented here. The fact that recurrences or relapses are likely to occur within the first few months following completion of an iv antibiotic course makes close follow-up of patients beyond this time important. It is possible that other, non-infective aspects of patient care, such as diabetic control, wound care and nutritional support, Mackintosh et al.
become increasingly important as contact with medical and nursing services declines following completion of the initial therapy. Longer iv courses of antibiotics, prolonged oral therapy, nutritional support and a gradual step-down approach to completion of therapy have all been suggested as possible means of reducing relapse. 12 -14 We show clearly very poor outcomes associated with diabetic-related osteoarticular infection, both after the initial prescribed iv antibiotic course and over the subsequent follow-up period. In support of this finding, a study from the USA in 2003 demonstrated that co-morbidity with diabetes resulted in a relative risk of recurrence of osteomyelitis of 4.9, with an overall cure rate, measured at varying timepoints, of 69.4%. 12 This work also demonstrated an association with poor outcome in those with peripheral vascular disease. In a previous analysis of OPATtreated DFI in our unit, we observed high rates of peripheral vascular disease (70%), which was frequently associated with retreatment with antibiotics and anticipated but limited amputation of the infected bone. 15 These cases would be classified as OPAT failures within this current analysis, although the benefit of avoiding prolonged hospitalization during a therapeutic trial of antibiotic therapy was still recognized by the referring clinicians. Previous work in DFI has also described an association of poor outcome with body mass index, duration of diabetes and overall diabetic control. 16, 17 In addition, work examining outcome in diabetic-related osteomyelitis and skin and soft tissue infection revealed that Pseudomonas was the second most frequently isolated pathogen, and was associated with poorer outcome. 17 In contrast, in this cohort, Pseudomonas was isolated on five occasions, only two of which were in DFI. The reasons for this difference are not entirely clear, but most likely reflect the higher proportion of positive cultures obtained from deep tissue in the earlier work and the high proportion of cultures from unknown sources in our study.
In keeping with published data on osteoarticular infections, S. aureus was the most commonly isolated pathogen, 5,9,10,18 -20 of which 60.2% of isolates were MRSA. This represents a higher burden of MRSA than that in previously published cohorts from the USA, 10, 12 but is more in line with rates from Australia and 20 -22 The association of MRSA with both poor initial outcome and longer term failure is interesting, and does not appear to be related to length of iv treatment, advanced age or underlying diagnosis. The retrospective nature of our work makes more subtle investigation of those with MRSA, such as co-morbidity, body mass index or previous history, not possible. As all MRSA-infected patients were treated with teicoplanin (usually with a second oral agent), it was not possible to compare outcomes with other newer anti-MRSA agents, such as linezolid or daptomycin. It has been postulated that glycopeptides may not be optimal treatment for osteoarticular infections, due to relatively poor tissue penetration and declining cidality; however, they do remain standard therapy in most countries and, particularly, in the OPAT setting.
This study has a number of limitations. Most importantly, this was a retrospective review of case notes and, as such, randomization was not possible. Also, we were unable to accurately collect detailed information regarding important variables such as timing of surgery relative to infection in the case of the prosthetic joints, decisions regarding further surgery or debridement, radiological findings and detailed source data on many microbiological samples. Lack of data regarding co-morbidities, specifically peripheral vascular disease and any immune-modifying medications or conditions, resulted in these not being included in the analysis and it is likely that these may have had a bearing on individual outcomes. In 15.7% of cases there was no positive microbiology identified and it remains possible that in some of these cases infection was not responsible for the presentation.
Whilst acknowledging the heterogeneity of the clinical cases presented, nevertheless, these data provide useful information regarding the use of OPAT to manage a diverse range of BJIs. The data provide some insight into the prognosis of these conditions as well as possible factors that may aid the identification of those patients with a likelihood of poorer outcome. From a practical point of view, these data may encourage enhanced vigilance and consideration of newer or more aggressive treatments in patients at higher risk of treatment failure (such as those with MRSA infection or diabetes-related infections). The data may also provide useful information on patient selection for those who are developing OPAT services. Further prospective studies looking at optimal treatment durations and treatment modalities as well as the identification of measures that may reduce the high relapse rate amongst those with diabetic co-morbidity are needed.
